Zacks Research Has Bearish Estimate for Omnicell Q3 Earnings

Omnicell, Inc. (NASDAQ:OMCL) – Equities research analysts at Zacks Research reduced their Q3 2026 earnings per share estimates for shares of Omnicell in a report issued on Friday, August 14th. Zacks Research analyst Team now expects that the company will earn $0.25 per share for the quarter, down from their previous estimate of $0.27. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Omnicell’s current full-year earnings is $1.30 per share. Zacks Research also issued estimates for Omnicell’s Q4 2026 earnings at $0.07 EPS, FY2026 earnings at $1.49 EPS, Q1 2027 earnings at $0.25 EPS, Q2 2027 earnings at $0.23 EPS, Q3 2027 earnings at $0.32 EPS, Q4 2027 earnings at $0.47 EPS, FY2027 earnings at $1.27 EPS and FY2028 earnings at $1.73 EPS.

Other equities research analysts also recently issued research reports about the company. Wells Fargo & Company dropped their target price on Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Weiss Ratings reiterated a “hold (c-)” rating on shares of Omnicell in a research note on Tuesday, August 4th. Wall Street Zen raised Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. Piper Sandler reaffirmed an “overweight” rating and set a $45.00 target price (down from $55.00) on shares of Omnicell in a report on Monday, August 3rd. Finally, Craig Hallum reiterated a “buy” rating and set a $55.00 price target on shares of Omnicell in a research report on Wednesday, April 29th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $57.86.

Omnicell Stock Down 0.2%

Omnicell stock opened at $35.97 on Wednesday. Omnicell has a 1-year low of $29.06 and a 1-year high of $55.00. The firm has a market capitalization of $1.64 billion, a price-to-earnings ratio of 42.82, a P/E/G ratio of 1.01 and a beta of 0.98. The company has a current ratio of 1.64, a quick ratio of 1.43 and a debt-to-equity ratio of 0.13. The firm has a 50 day simple moving average of $40.50 and a 200 day simple moving average of $39.89.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.47. The business had revenue of $312.21 million for the quarter, compared to analysts’ expectations of $310.21 million. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The firm’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS.

Institutional Trading of Omnicell

Hedge funds have recently bought and sold shares of the company. BlackRock Inc. bought a new position in Omnicell during the second quarter valued at approximately $313,044,000. Dimensional Fund Advisors LP raised its position in Omnicell by 6.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company’s stock worth $81,791,000 after purchasing an additional 137,834 shares during the period. Wellington Management Group LLP lifted its stake in Omnicell by 156.4% in the fourth quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock worth $94,014,000 after purchasing an additional 1,265,818 shares during the last quarter. Lazard Asset Management LLC boosted its position in Omnicell by 3.8% during the second quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock valued at $50,225,000 after buying an additional 62,733 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Omnicell by 2.0% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,410,865 shares of the company’s stock valued at $47,095,000 after buying an additional 27,497 shares during the last quarter. Institutional investors own 97.70% of the company’s stock.

Key Headlines Impacting Omnicell

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Zacks raised its FY2026 EPS estimate to $1.49 from $1.27, above the broader consensus estimate of $1.30. It also increased its Q4 2027 forecast to $0.47 from $0.37 and FY2028 forecast to $1.73 from $1.71, suggesting some longer-term earnings potential.
• Neutral Sentiment: Zacks’ updated estimates call for FY2027 EPS of $1.27, FY2028 EPS of $1.73, and current-year consensus EPS of $1.30. The revisions indicate uncertainty about the timing and durability of Omnicell’s earnings growth.
• Negative Sentiment: Near-term estimates were cut across several periods: Q3 2026 EPS to $0.25 from $0.27, Q4 2026 to $0.07 from $0.31, Q1 2027 to $0.25 from $0.31, and Q2 2027 to $0.23 from $0.32. The sharp Q4 2026 reduction is particularly negative because it implies weaker profitability in the upcoming quarter.
• Negative Sentiment: Zacks lowered its FY2027 EPS forecast to $1.27 from $1.34. Combined with the firm’s “Strong Sell” rating, the revisions reinforce concerns about Omnicell’s near-term earnings trajectory despite the higher FY2026 estimate.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.